NLS Pharmaceutics (NLSP)
NASDAQ:NLSP
US Market
Holding NLSP?
Track your performance easily

NLS Pharmaceutics (NLSP) Income Statement

198 Followers

NLS Pharmaceutics Income Statement

Last quarter (Q ), NLS Pharmaceutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, NLS Pharmaceutics's net income was $―. See NLS Pharmaceutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
--$ 16.30M-$ 2.30M$ 0.00
Cost of Revenue
------
Gross Profit
--$ 16.30M-$ 2.30M-
Operating Expense
-$ 11.81M$ -15.48M$ 11.86M$ 2.30M$ 4.20M
Operating Income
-$ -11.81M$ -15.48M$ -11.86M$ -2.30M$ -4.20M
Net Non Operating Interest Income Expense
-$ -145.15K$ -100.87K$ -68.13K$ -233.70K$ -819.71K
Other Income Expense
-$ 219.81K$ -110.99K$ 17.32K$ 329.05K$ -430.39K
Pretax Income
-$ -12.17M$ -15.47M$ -12.08M$ -2.86M$ -5.45M
Tax Provision
--$ -1.00M$ -1.12M$ -384.30K-
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-$ -12.17M$ -16.39M$ -12.08M$ -2.86M$ -5.45M
Basic EPS
-$ -0.32$ -0.84$ -1.00-$ -0.46
Diluted EPS
-$ -0.32$ -0.84$ -1.00-$ -0.46
Basic Average Shares
-$ 38.18M$ 19.68M$ 11.90M$ 6.96M$ 11.78M
Diluted Average Shares
-$ 38.18M$ 19.68M$ 11.90M$ 6.96M$ 11.78M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-$ 11.81M$ -15.48M$ 11.86M$ 2.30M$ 4.20M
Net Income From Continuing And Discontinued Operation
-$ -12.17M$ -16.50M$ -12.08M$ -2.86M$ -5.45M
Normalized Income
-$ -8.95M---$ -5.08M
Interest Expense
-----$ 819.71K
EBIT
-$ -12.03M$ -15.37M$ -12.01M$ -2.65M$ -4.63M
EBITDA
-$ -12.02M$ -15.30M$ -11.96M$ -2.58M$ -4.63M
Currency in USD

NLS Pharmaceutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis